<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804284</url>
  </required_header>
  <id_info>
    <org_study_id>M5A11</org_study_id>
    <nct_id>NCT00804284</nct_id>
  </id_info>
  <brief_title>Database Surveillance Safety Study of PENTACEL® Vaccine</brief_title>
  <official_title>Post-Licensure Safety Surveillance Study of Routine Use of PENTACEL® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective for this study is to characterize the safety profile of PENTACEL® vaccine for&#xD;
      identification of potential vaccine-related adverse events not currently associated with&#xD;
      PENTACEL® vaccine administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at Kaiser Permanente Northern California and will commence with&#xD;
      first use of licensed PENTACEL® vaccine within that organization.&#xD;
&#xD;
      Vaccination databases will be reviewed to identify Diphtheria and tetanus toxoid with&#xD;
      acellular pertussis (DTaP) vaccinations of accrued subjects. Medical encounter, emergency&#xD;
      room, hospitalization, laboratory, state death reporting, and related databases will be&#xD;
      reviewed to identify medical care events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>A summary of all non-elective hospitalization and emergency room visits as well as outcome of interest from chart review.</measure>
    <time_frame>Up to 6 months post -dose 4 DTap Vaccination</time_frame>
    <description>Outcome of interest identified from Kaiser Permanente Medical Care Program (KPMCP) computerized records via International Classification of Diseases, 9th edition (ICD-9) codes, defined as:&#xD;
Death,&#xD;
Outpatient clinic visit for:&#xD;
seizure occurring within 72 hours of vaccination, Guillain-Barré Syndrome, encephalopathy, encephalitis, alteration of consciousness (other than secondary to another diagnosis), or meningitis&#xD;
hypersensitivity reactions (e.g. urticaria, angioedema, or anaphylaxis) occurring within 72 hours of vaccination,&#xD;
new-onset autoimmune disease (including idiopathic thrombocytopenic purpura, hemolytic anemia).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">62538</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Haemophilus Influenzae</condition>
  <arm_group>
    <arm_group_label>Pentacel Group</arm_group_label>
    <description>Infants initiated on PENTACEL® vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other DTap vaccines Group</arm_group_label>
    <description>Infants initiated on other DTaP vaccines</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV/Hib</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Pentacel Group</arm_group_label>
    <other_name>PENTACEL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Other DTap Vaccines</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Other DTap vaccines Group</arm_group_label>
    <other_name>DAPTACEL®</other_name>
    <other_name>INFANRIX®</other_name>
    <other_name>PEDIARIX®</other_name>
    <other_name>TRIPEDIA®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Receipt of DTaP vaccine during the study period by a previously unvaccinated subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receipt of DTaP vaccine during the study period by a previously unvaccinated child&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAPTACEL®</keyword>
  <keyword>PENTACEL®</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

